Sana Biotechnology Inc. $(SANA)$, a company focused on developing engineered cell therapies, has announced an upcoming presentation of updated six-month clinical results at the 85th Annual American Diabetes Association Scientific Sessions. The presentation will detail ongoing data from a first-in-human study of UP421, an allogeneic primary islet cell therapy modified with Sana's hypoimmune technology, designed for patients with type 1 diabetes. This study uniquely involves the transplantation of cells without the use of immunosuppression. The presentation is scheduled to occur during a joint ADA/International Pancreas & Islet Transplant Association symposium on June 23, 2025, in Chicago, IL, from 9:00 to 9:20 a.m. CT.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。